1426 / 1674
Clinical studies
Author year N Treatment
Cancer
site
Endpoint
Rando-
mized
Blinde
d
Effect
Delanian S
1999
43 Pentox. 400 mg x 3
Vit. E 500 IU x 2
Breast
H&N
Fibrosis area, LEND-
SOMA , pain
No
No
Yes
Delainan S
2003
22 Pentox. 400 mg x 2
Vit. E 500 IU x 2
Breast
Fibrosis area, LEND-
SOMA , pain
Yes
Yes
No
Delanian S
2005
44 Pentox. 400 mg x 2
Vit. E 500 IU x 2
Breast
Fibrosis area, LEND-
SOMA , pain
No
No
Yes
Futran ND
1997
26 Pentox. 400 mg x 3 Mixed
Mixed
No
No
Yes
Gothard L
2004
68 Pentox. 400 mg x 2
Vit. E 500 IU x 2
Breast
Oedema, induration
Yes
Yes
No
Jacobson G
2013
53 Pentox. 400 mg x 2
Vit. E 500 IU x 1
Breast
Tissue compliance
meter meassurement
Yes
No
Yes
Magnusson M
2009
83 Pentox. 400 mg x 2
Vit. E 100 mg x 1
Breast
Arm oedema, sholder
movement
Yes
Yes
yes
Okunieff P
2004
27 Pentox. 400 mg x 3 Mixed
Mixed
No
No
Yes
Adapted fromWestbury and Yarnold 2012